Buy & Sell Okta, Inc. (OKTA) – Okta, Inc. Price Today
Aura AI Summary
Key Stats
- $15.26BMarket Cap
- TechnologySector
- -22.4%3M Drawdown
- $13.13BEnterprise Value
- -Dividend Yield
- 48% Buy | 52% SellTrading Activity
- 53 daysTypical Hold Time
Okta, Inc. (OKTA) is currently valued at a market capitalization of $15.26B, with an enterprise value of $13.13B. Over the past 52 weeks, Okta, Inc. has traded between a low of $62.93 and a high of $126.44, highlighting its annual price range. Over the past three months, Okta, Inc. has recorded a drawdown of -22.4%, reflecting recent price volatility. On average, investors hold Okta, Inc. for approximately 53 days, indicating typical investor behavior on the platform.
About Okta, Inc.
Okta is a cloud-native security company that focuses on identity and access management. The San Francisco-based firm went public in 2017 and focuses on two key client stakeholder groups: workforces and customers. Okta's workforce offerings enable a company's employees to securely access its cloud-based and on-premises resources. The firm's customer offerings allow its clients' customers to securely access the client's applications.
Most Recent News
Short seller warns Everspin stock is overvalued amid AI hype, predicts 60% downside.
Kerrisdale Capital has taken a short position on Everspin Technologies, arguing the recent surge in its stock price is driven by misplaced enthusiasm around AI-related memory demand. Everspin's MRAM technology targets niche industrial markets rather ...

Vuzix showcases advanced waveguide smart glasses for defense at SOF Week 2026 in Florida
Vuzix Corporation is exhibiting its advanced AI-powered smart glasses and waveguide solutions at SOF Week 2026 in Tampa, Florida. These products are designed for defense use, offering mission-ready optical performance in challenging environments, inc...

Over 50 companies advance 55+ new pulmonary arterial hypertension drugs in clinical trials.
More than 50 companies are actively developing over 55 new drugs for pulmonary arterial hypertension (PAH), a serious lung-related heart condition. These drugs are in various clinical trial stages, with several in late-stage development, aiming to im...
